It is estimated that 10-18% of men have problems with inability to ejaculate, decreased volume of ejaculation, decreased force of ejaculation and delayed time to ejaculation. This is a neurobiological problem from erectile dysfunction and there is no FDA-approved treatment for this condition. A new study has revealed that the common testosterone replacement therapy is no guarantee to treat ejaculatory dysfunction in men to improve sex life.
Darius A. Paduch of the New York-Presbyterian Hospital said, "This trial examines the treatment of a very common but poorly understood condition that affects men's physical health as well as their interpersonal relationships. Although the participants in this study did not experience any significant improvement in ejaculatory function, we hope our work will spur the development of additional clinical trials to find treatments for this condition."
For the study, 76 men with ejaculatory dysfunction were assigned to receive either a 2% testosterone solution applied on the skin or a placebo. 66 men completed the study, and to gauge ejaculatory function, researchers collected semen samples and had participants complete sexual health questionnaires and logs. The researcher team found no or little improvement in ejaculate volume or orgasmic function in men who received the testosterone replacement therapy.
Shehzad Basaria from Brigham and Women's Hospital and Harvard Medical School in Boston said, "Our results suggest physicians who are treating men with ejaculatory dysfunction need to look at other reasons for delayed ejaculation than hypogonadism. Hypogonadism is a condition that results from low testosterone levels."
The authors suggested the need for more research to determine whether a longer course of testosterone therapy or other treatment options can benefit men with ejaculatory dysfunction.
The study appeared in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.